REACT

ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022

Retrieved on: 
Friday, October 14, 2022
U.S. Securities and Exchange Commission, ASN, Risk, Chronic kidney disease, Growth, Population, Humanitarian use licenses, Diagnosis, EMA, RWD, Society, Patient, Research, Security (finance), Mortality, Partnership, Nasdaq, Technology, Private Securities Litigation Reform Act, Renal replacement therapy, Company, Marketing, Disease, REACT, GLOBE, Kidney, CKD, FDA, COVID-19, Pharmaceutical industry

WINSTON-SALEM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present five posters on REACT and CKD at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held November 3-6, 2022, in Orlando, FL.

Key Points: 
  • To register for the event, or for additional information, please contact Dr. Glenn Schulman at [email protected] .
  • Following the event, a copy of the presentation slides will be available on the Companys website at https://investors.prokidney.com/news-events/events-and-presentations .
  • ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research.
  • Notably, the 5-year mortality of newly diagnosed Stage 4 CKD is higher than that of newly diagnosed non-metastatic cancer.

At Clinton Global Initiative, Welcome.US Announces Commitment to Engage 50,000 More Americans in Sponsoring Refugees Over Next Three Years

Retrieved on: 
Tuesday, September 20, 2022
University, ServiceNow, HIAS, Engineering, Movement, First lady, NEW, Organization, Clinton Foundation, Goldman Sachs, Partnership, Government, Heroes Welcome UK, Technology, Veteran, Private sector, CGI, Solution, Friends, Infosys, International Rescue Committee, REACT, Refugee, Commitment, International, Conference, Bishops in the Catholic Church, Awareness, Multimedia, Mobile phone, Pharmaceutical industry, Renewable energy, Management, Sex industry

NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Today, Welcome.US announced a new commitment to help an additional 50,000 Americans to sponsor refugees over the next three years. Working in partnership with some of the most iconic and effective nonprofit and faith organizations in the United States — including Alight, Church World Service, Community Sponsorship Hub, HIAS, the International Rescue Committee, REACT DC, The Shapiro Foundation, Migration and Refugee Services/United States Conference of Catholic Bishops, and WelcomeNST, Welcome.US — the coalition will create a network of community and civic organizations to mobilize tens of thousands of Americans to sponsor newcomers and provide vital support.

Key Points: 
  • At Clinton Global Initiative, Welcome.US announces commitment to engage 50,000 more Americans in sponsoring refugees.
  • CGI's unique model supports its partners in developing Commitments to Action, new, specific, and measurable projects to address pressing global challenges.
  • "Now, we are tapping into this newfound potential by announcing a Commitment to Action to engage 50,000 more Americans in sponsorship over the next three years.
  • The Clinton Global Initiative (CGI) convenes global and emerging leaders to create and implement solutions to the world's most pressing challenges.

European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types

Retrieved on: 
Wednesday, September 7, 2022
Digital, Neoplasm, Partnership, COVID-19, CEO, Cancer, Research, ESF, Infection, ERDF, REACT, Data collection, Founder, Gesellschaft mit beschränkter Haftung, Drug development, Pandemic, Medical device, Pharmaceutical industry, Medical imaging, EU

BERLIN and HAMBURG, Germany, Sept. 7, 2022 /PRNewswire/ -- Indivumed GmbH ("Indivumed") and CELLphenomics GmbH ("CELLphenomics") today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed's AI-driven oncology analytics with CELLphenomics' expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.

Key Points: 
  • The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.
  • "By partnering with CELLphenomics, we will be able to quickly validate therapeutically relevant targets to identify new treatment approaches and accelerate cancer drug development in the future."
  • The partnership announcement comes after Indivumed was awarded 4.3 million by the European Union Structural Fund ERDF to accelerate drug development and personalize treatments for cancer.
  • Indivumed's analytical platform, nRavel , will identify, characterize, and prioritize potential targets for the selected tumor types.

AI SpaceFactory and NASA Kennedy Space Center Release Lunar Outpost Designs

Retrieved on: 
Thursday, June 30, 2022
Construction, ACO, Travel, 3D, Printing, Romanesque, Robotics, REACT, SpaceX, Planet, NASA, KSC, Swamp Works, Environment, Technology, Radiation, LINA, NEW, AI, Blue Origin, 3D printing, Mars, Moon

NEW YORK, June 30, 2022 /PRNewswire/ -- Today, space architecture and technology firm AI SpaceFactory announced its designs for LINA, the first lunar outpost developed in collaboration with NASA Kennedy Space Center (KSC) engineers and planetary scientists.

Key Points: 
  • The technologies behind the 3D printed structure, called LINA, could support a near-future human foothold on the moon
    NEW YORK, June 30, 2022 /PRNewswire/ -- Today, space architecture and technology firm AI SpaceFactory announced its designs for LINA, the first lunar outpost developed in collaboration with NASA Kennedy Space Center (KSC) engineers and planetary scientists.
  • The results will inform a sustainable 3D printing system capable of constructing large structures on the Moon's surface with which AI SpaceFactory plans to ultimately use to print LINA.
  • "Our Mars habitat prototype MARSHA proved that 3D printing with a polymer composite was a strong solution for habitation off-world," said AI SpaceFactory CEO David Malott.
  • AI SpaceFactory develops advanced construction technologies for space exploration autonomous robotics and sustainable materials which will transform how we build and live on Earth.

ProKidney Corroborates the Mechanism of Action of REACT™ with Cell Marker Analysis in Patients with Diabetic Chronic Kidney Disease

Retrieved on: 
Thursday, June 23, 2022
Fibrosis, Chronic kidney disease, Population, FDA, Safety, Inflammation, Tissue, Glomerular filtration rate, EGFR, Kidney, Dialysis, CEO, San Rafael, California, Time, Immunosuppression, Proteomics, Founder, Calcium, Metabolic syndrome, BLA, Urine, FACS, Program, Vascular endothelial growth factor A, CKD, ESRD, American Journal, Caregiver, Injection, Phosphorus, Standard of care, Patient, Biologics license application, VEGF, Cell, REACT, Blood, GLOBE, Dissection, Pharmaceutical industry, Medical imaging, Nephrology

Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis by Joseph Stavas et.

Key Points: 
  • Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action with Cell Marker Analysis by Joseph Stavas et.
  • This publication is further evidence that REACT may successfully stabilize and improve kidney function in patients with moderate to severe diabetic CKD, said Dr. Tim Bertram, CEO and Founder of ProKidney.
  • The injection procedure of REACT is done on an outpatient basis with placement in the cortex of the patients kidney.
  • Fluorescent Activated Cell Sorting (FACS) analysis for renal progenitor lineages in REACT and vascular endothelial growth factor A (VEGF-A) analysis were performed.

ProKidney highlights key registrational program elements supporting advancement of REACT®

Retrieved on: 
Tuesday, May 3, 2022
EGFR, Standard of care, Time, CKD, GLOBE, Chronic kidney disease, Medicine, Kidney, Safety, Glomerular filtration rate, Food, Regenerative medicine, ESRD, Injection, Patient, BLA, Immunosuppression, Trial of the century, Review, Founder, Program, FDA, Dialysis, Biologics license application, Disease, CMC, CEO, REACT, Cell, Pharmaceutical industry, Medical imaging, Medical device, Chemistry

With the grant of RMAT designation for REACT, the FDA is providing ProKidney in-depth guidance on the REACT registrational program.

Key Points: 
  • With the grant of RMAT designation for REACT, the FDA is providing ProKidney in-depth guidance on the REACT registrational program.
  • The Phase 3 program will be conducted in multiple centers in the United States, Europe, Latin America, and Asia Pacific.
  • This long-term follow-up program could provide robust evidence in support of premium pricing and product durability for REACT.
  • Neither ProKidney nor SCS gives any assurance that either ProKidney or SCS, or the combined company, will achieve its expectations.

Realist evaluation framework guides improvement of pediatric rapid response system

Retrieved on: 
Tuesday, March 29, 2022
Transfer, Ventilation, Gaps, RRS, Patient safety, Review, Baylor College of Medicine, Mortality, Editorial, Quality, FRCP, Doctor of Philosophy, RN, Hospital, CNE, MPH, Arrest, GLOBE, The Meadows of the Righteous, REACT, CPA, RR, ICU, Patient, Pharmaceutical industry, MD

Because evaluations of RR systems traditionally rely on CPA and mortality, rare in children, alternative pragmatic metrics for pediatric RR evaluation are needed.

Key Points: 
  • Because evaluations of RR systems traditionally rely on CPA and mortality, rare in children, alternative pragmatic metrics for pediatric RR evaluation are needed.
  • The team developed a new metric called REACT (Rapid Escalation After Critical Transfer) to review clinical outcomes after RR events to appraise pediatric RR systems and identify improvement opportunities.
  • The researchers applied the realist evaluation (context-mechanism-outcomes) framework to review significant RRs defined as REACT events, including all with CPA and/or ventilation and/or hemodynamic support instituted within 24 hours after RR.
  • Findings showed after five years:
    The realist evaluation framework facilitated a holistic assessment of an RR system.

Idorsia announces financial results for 2021 – 2022 to be a transformative year – Sustainable profitability expected in 2025

Retrieved on: 
Tuesday, February 8, 2022
Fabry disease, Cerebral vasospasm, Hypertension, Letter, European Medicines Agency, Binge eating disorder, Essential tremor, AGM, Standard Business Reporting, Annual, ASAH, Lupus, REACT, The Lancet, Research, COVID-19, FDA, Neurocrine Biosciences, Method, Epilepsy, CARE, Drug discovery, Night, Risk, Patient, Review, IDIA, EMA, SIX Swiss Exchange, Janssen Pharmaceuticals, Documentation, Johnson & Johnson, Insomnia, Result, Ponesimod, Income, Science, Board, Annual report, CMO, Heart, Janssen Biotech, Population, CEO, Mission statement, Corporation, Intelligence, Vaccine, Pharmaceutical industry, Animal, Online gambling, Security (finance), Renewable energy, Fine chemical, Management, Risk management, Shareholder, Actelion

Idorsia created 268 new positions worldwide in 2021, bringing the total number of employees (permanent, post-doc, and apprentices) to 1176 (2020: 908).

Key Points: 
  • Idorsia created 268 new positions worldwide in 2021, bringing the total number of employees (permanent, post-doc, and apprentices) to 1176 (2020: 908).
  • My role and that of the Board is to provide direction and oversight, as well as governance of the organization.
  • We are building Idorsia with a long-term focus, and we run the company in a responsible and sustainable way.
  • In 2021, we made great strides toward realizing our vision of creating a sustainable mid-sized biopharmaceutical company based on innovation.

Tiberium Tops off Four-fold Growth in Customer Base With Invitation to Join Microsoft MISA

Retrieved on: 
Tuesday, February 1, 2022
Software, Technology, Security, Sentinel, Growth, Solution, Risk, Automation, Security, Ecosystem, Environment, Security association, Partnership, REACT, Hunting, MSSP, News, Defender, Multimedia, Risk management, Video game console, Command & Conquer 3: Tiberium Wars, Microsoft

Innovation and automation focused MSSP, Tiberium , today announced a further development in its collaboration with Microsoft by joining the Microsoft Intelligent Security Association (MISA).

Key Points: 
  • Innovation and automation focused MSSP, Tiberium , today announced a further development in its collaboration with Microsoft by joining the Microsoft Intelligent Security Association (MISA).
  • The announcement follows the news last year of the launch of Tiberium FROST and MYTHIC to Tiberium s Managed Cyber Defence Centre offering (MSSP).
  • Parri Munsell, Managing Director, Security Partner Marketing at Microsoft states, I am pleased to have Tiberium join us as a partner in the Microsoft Intelligent Security Association (MISA).
  • Drew Perry, Chief Executive Officer at Tiberium , comments: Our strategic partnership with Microsoft and Tiberiums rapid growth is no coincidence.

The Lancet Regional Health - Europe publishes 'real-world evidence' from ALK-sponsored study confirming long-term benefits of allergy immunotherapy in allergic rhinitis and asthma

Retrieved on: 
Wednesday, December 1, 2021
Patient, OMX, Safety, Mental health, SQ, AR, REACT, Asthma, Diagnosis, Research and development, ALK, AIT, Degenerative disease, Health policy, Risk, Anaphylaxis, Infection, Development, Nasdaq Copenhagen, Pneumonia, Allergy, Immunotherapy, Multimedia, Allergic rhinitis, Pharmaceutical industry, Medicinal plants, Health insurance

The study was authored by leading experts in the field of allergy immunotherapy and real-world evidence.

Key Points: 
  • The study was authored by leading experts in the field of allergy immunotherapy and real-world evidence.
  • The primary objective of the study was to assess the impact of AIT on the use of symptomatic treatments by people with allergic rhinitis (AR), with or without asthma.
  • Patients with pre-existing asthma treated with AIT were more likely to step down their asthma treatment regimens, with a reduced likelihood of stepping up again.
  • It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors.